Skip to content

Public FDA record

Z-1670-2021: Access SARS-CoV-2 Antigen, REF C68668, UDI: (01)15099590742713, 3.30 mL/R1a, 4.70 mL/R1b, 4.20 mL/R1c, 3.

Recall record Z-1670-2021 for Beckman Coulter Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1670-2021
Company in FDA record
Beckman Coulter Inc.
FDA record creation date
May 21, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

specimens collected in transport media may result is false negative results when stored in certain conditions.

Source facts

Action
On 4/14/2021, Becman Coulter issued an "Urgent Medical Device Recall" notice to all affected consignees via mail and E-Mail. In addition to informing consignees about the recall, the firm ask consignees to take the following actions: 1. Review the laboratory storage conditions for nasopharyngeal or nasal specimens that are collected in Bartels FlexTrans" and Sigma Virocult transport media. Evaluate the specimen storage conditions before and after extraction. 2 Review test results in the context of a patients history and clinical presentation for any specimens that were not stored according to the guidelines provided in the following tables: Before Extraction: Transport Media, Bartels FlexTrans Transport Medium Sigma Virocult, Revised Stability, 20-25C, 6 hrs. , 2-8C, 33 hrs. After Extraction: Transport Media, Bartels FlexTrans Transport Medium Sigma Virocult, Revised Stability, 20-25C, 10 min - 3 hrs., 2-8C, 6 hrs. 3. Limit of Detection: A. The LoD for specimens collected in Bartels FlexTrans" transport media has been amended from 33 TCID50/mL to 139 TCID50/mL. B. No action is required in relation to the change in the limit of detection for Bartels FlexTrans" transport media. C. Update internal laboratory documentation as required. 4. Please share this information with your laboratory staff and retain this notification as part of your laboratory Quality System documentation. If you have forwarded any of the affected product listed above to another laboratory, please provide them a copy of this letter. 5. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDAs MedWatch Adverse Event Reporting program either online, by regular mail or by fax. 6. Please complete and return the enclosed Response Form within 10 days so we are assured you have received this important communication. 7. If you have any questions regarding this notice, please contact our Customer Support Center:
Initiated
2021-04-14
Root cause
Unknown/Undetermined by firm
Terminated
2023-05-19
Distribution
Worldwide distribution - US Nationwide distribution in the states of Alabama, Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, New Hampshire, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Tennessee, Texas, Virginia, West Virginia and the country of New Zealand.
Recall number
Z-1670-2021
Recall status
Terminated
CDRH record ID
186886
FDA record created
2021-05-21
Recall event number
87738

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗